The Global Fund provides about 50 percent of all malaria international assistance, and with the world’s second largest contributor (the U.S. government), accounts for about 75 percent of all funding for global malaria projects, programs and policies. Launched in 2005 by President George W. Bush and expanded under President Barack Obama, PMI is a historic U.S. government effort to provide global technical and financial leadership in the fight against malaria. In developing its operational plans, PMI has sought, from the beginning, to complement the Global Fund, working only in countries where the Fund has a presence, assessing available resources and filling unmet needs. This is accomplished through the rapid scale up of four proven and highly effective malaria prevention and treatment measures: insecticide-treated mosquito nets (ITNs); indoor residual spraying (IRS); diagnosis and treatment with artemisinin-based combination therapies (ACTs); and intermittent preventative treatment of pregnant women (IPTp).

Currently, all 19 PMI focus countries in Africa — as well as a regional program in the Greater Mekong sub-region of Southeast Asia — receive substantial funding from the Global Fund. The Global Fund and PMI are able to achieve greater results together: According to the World Health Organization’s (WHO) 2014 World Malaria Report, the malaria mortality rates in children under age 5 in Africa were reduced by an estimated 58 percent between 2000 and 2013. Furthermore, more than 155 million ITNs have been procured, and 102 million have been distributed since PMI’s inception. In addition, PMI has distributed more than 243 million lifesaving antimalarial treatments and 107 million rapid diagnostic tests. According to the United Nation’s 2015 Millennium Development Goals (MDGs) report, global investments to fight malaria have helped avert more than 6.2 million deaths from 2000-2015, and 98 malaria-burdened countries have reversed their incidence rates, meeting the MDG target and moving toward elimination. The U.S. government’s financial and technical contributions, as well as those of the Global Fund, have played a major role in this remarkable progress.

The collaboration between PMI and the Global Fund has facilitated great progress, yet malaria remains a serious public health problem. With the growing threat of artemisinin drug resistance and the need to replace ITNs, continuing coordination between the Global Fund and PMI is critical to achieving the shared vision of a world free from malaria.